Skip to main content

Phytotherapy for LUTS / BPH

Phytotherapy for LUTS/BPH requires product-specific counseling.[1][31][32] EAU 2026 weakly recommends offering hexane-extracted Serenoa repens to men with LUTS who want to avoid adverse effects, particularly sexual effects.[23] It strongly recommends counseling that the benefit may be modest.[23] The AUA 2026 LUTS/BPH guideline makes no recommendation for or against herbal products.[25]

This article covers the four agents that dominate the BPH/LUTS phytotherapy literature: saw palmetto (Serenoa repens), β-sitosterol, pumpkin seed (Cucurbita pepo), and Pygeum africanum, with the evidence with priority given to placebo-controlled studies and current guidance. Cernilton (rye-grass pollen extract) is noted at the end of the agent sections. For medical therapy, see the α-blocker and 5-ARI articles; the EAU recommends 5-ARIs for men with moderate-to-severe LUTS and increased progression risk (for example, prostate volume >40 mL; Strong).[23] For surgical options, see bladder outlet obstruction.

Why Phytotherapy Lives in "Legacy & Low-Evidence"​

  • Limited evidence and product-specific guidance. Established LUTS drugs and progression-directed 5-ARI therapy have a different evidence base. Arnold et al. discuss 5-ARIs for uncontrolled LUTS with prostate volume at least 30 mL.[1] EAU 2026 strongly recommends a 5-ARI for men with moderate-to-severe LUTS and increased progression risk (for example, prostate volume >40 mL), without requiring an α-blocker trial.[23]
  • Heterogeneous products. The hexanic lipidosterolic extract of Serenoa repens (Permixon) behaves differently from ethanolic extracts; non-glucosidic β-sitosterol differs from the β-D-glucoside form; pumpkin-seed "extract" is not a single entity.[5][11] EAU 2026 lists the EMA herbal committee (HMPC) monographs: only hexane-extracted Serenoa repens has well-established use for symptomatic BPH, whereas ethanol-extracted saw palmetto, pumpkin seed, Prunus africana bark, nettle root and willow herb are traditional use only.[23] The EAU panel notes that batches from one producer can differ in active content.[23]
  • Signal-to-noise problem. The best-designed, large-scale placebo-controlled RCTs (CAMUS 2011, STEP 2006) are negative for saw palmetto; positive meta-analyses rely heavily on older, smaller trials and observational data with heterogeneous extracts.[2][4]
  • Trial tolerability is generally favorable. Check the exact ingredients, concurrent drugs and adverse effects.[5][16][21]

Agents in This Class​

AgentExtract / preparationStudied daily doseProposed mechanismGuideline position
Saw palmetto (Serenoa repens)Hexanic (Permixon) and other extracts differ; 320 mg/day[3][5]320 mg5α-reductase inhibition, anti-inflammatory, antiproliferativeAFP 2023 review: not effective[1]; EAU: weak, product-specific option[23]
β-sitosterolThree trials tested nonglucosidic preparations; WA184 tested β-D-glucoside alone and showed no flow improvement; Berges 1995 tested Harzol, a mixed-phytosterol preparation described in the trial as 20 mg β-sitosterol three times daily[11][12]Harzol (mixed phytosterols), reported as 20 mg β-sitosterol three times dailyPreclinical: a β-sitosterol-rich formulation inhibited contraction and stromal growth; isolated β-sitosterol weakly inhibited 5α-reductase[8][9]AFP 2023 review: may be effective[1]; no AUA or EAU recommendation[23][25]
Pumpkin seed (Cucurbita pepo)Hydroethanolic / soft extract; GRANU used extract 500 mg twice daily or whole seed 5 g twice daily[24]500 mg twice daily (extract)Cell-growth inhibition independent of steroid receptors[14]No guideline endorsement
Pygeum africanumStandardized bark extract; 100–200 mg/day[19][21]100 mgAnti-inflammatory (↓ leukotrienes, 5-LOX), antiandrogenic (NBBS), antifibroblast[19][20]AFP 2023 review: may be effective[1]; no AUA or EAU recommendation[23][25]

1. Saw Palmetto (Serenoa repens)​

The most widely used BPH phytotherapy worldwide. Mechanistically attractive (proposed 5α-reductase inhibition, anti-inflammatory, anti-androgenic, and antiproliferative effects), but none conclusively proven.[2][3]

The two evidence worlds:

CampKey dataConclusion
NegativeCAMUS (JAMA 2011) — n = 369, dose escalation 320 → 640 → 960 mg vs placebo × 72 wk. No dose of saw palmetto reduced LUTS more than placebo for AUASI, Qmax, PVR, QoL, or nocturia.[2] Cochrane 2023 — high-certainty evidence of statistically better urologic scores but differences of no clinical importance.[4]High-certainty overall finding of little/no clinically important benefit
Positive studies, differing preparations/designsVela-Navarrete 2018 meta-analysis — 27 studies / N = 5,800 across all arms (n = 3,926 received hexanic extract [Permixon]) — versus placebo, nocturia −0.64 voids/night (95% CI −0.98 to −0.31) and Qmax +2.75 mL/s (95% CI 0.57–4.93); IPSS improvement similar to α-blockers.[5] Ye 2019 Chinese multicenter placebo-controlled RCT — 354 randomized; IPSS, Qmax, QoL and sexual-function changes favored extract over placebo at 24 weeks.[6]Vela combined randomized and observational studies; in Ye's placebo-controlled trial, IPSS and Qmax changes favored the tested extract at 24 weeks.[5][6]

Preparation, study design and bias may contribute to different findings.[5][7] Generic "saw palmetto" supplements are not equivalent to Permixon hexanic extract.

Safety of hexanic extract (Permixon): generally well tolerated; gastrointestinal disorders had a mean incidence of 3.8%. Studies found no clinically relevant PSA effect (important for cancer screening) or relevant adverse effect on sexual function, a tolerability advantage over 5-ARIs.[3][5]

2. β-Sitosterol​

β-Sitosterol is a plant phytosterol reported in saw palmetto, Pygeum bark and pumpkin seeds.[15] Phytosterols recur across BPH phytotherapy preparations.[8]

Mechanism (modern preclinical work):

  • APOPROSTAT Forte formulation. In isolated human prostate tissue, this β-sitosterol-rich preparation inhibited adrenergic, non-adrenergic, and neurogenic contractions by 63–71%. The study also used the whole formulation for its stromal-cell assay; the active constituent was not identified.[8]
  • Stromal cell proliferation inhibited up to 67% at 72 h[8]
  • Weak 5α-reductase type 2 inhibition. IC₅₀ 3.24 μM, approximately 660-fold weaker than dutasteride (IC₅₀ 4.88 nM)[9]

Evidence:

  • Cochrane (Wilt 2000) (4 RCTs / n = 519): IPSS −4.9 (95% CI −6.3 to −3.5; 2 trials), Qmax +3.91 mL/s (95% CI 0.91–6.90; 4 trials), PVR −28.6 mL (95% CI −41.4 to −15.8; 4 trials).[10] No effect on prostate size.[10][11]
  • Berges 1995 Lancet RCT: In 200 randomized patients, Harzol (a mixed-phytosterol preparation reported as 20 mg β-sitosterol three times daily) reduced the modified Boyarsky score by 6.7 points versus 2.1 with placebo at six months. Among patients with six-month data, IPSS fell by 7.4 versus 2.1 points; mean Qmax rose from 9.9 to 15.2 mL/s and mean PVR fell from 65.8 to 30.4 mL in the treated group.[12]

Preparation caveat: Three of four trials used nonglucosidic preparations; the sole β-D-glucoside-only product (WA184) showed no improvement in urinary flow measures.[11] Without label transparency, the product risk is real.

Limitations: short trial durations (4–26 weeks), no long-term progression data, no data on whether it prevents BPH complications.[11]

3. Pumpkin Seed (Cucurbita pepo)​

Evidence is preparation-specific. The GRANU trial randomized 1,431 men to whole pumpkin seed, pumpkin-seed extract or placebo for one year. The primary responder outcome was a ≥5-point IPSS decrease. Extract did not differ from placebo; in the partially blinded whole-seed arm, 275/470 (58.5%) met this outcome versus 223/467 (47.8%) with placebo in the intention-to-treat, last-observation-carried-forward analysis. The whole-seed comparison was descriptive because confirmatory testing stopped after the negative extract comparison.[24][15][18]

Mechanism:

  • Inhibits hyperplastic prostate-cell growth approximately 40–50% in vitro[14]
  • The tested hydroethanolic pumpkin-seed extract and cucurbitin did not activate androgen, estrogen or progesterone receptors in yeast transactivation assays.[14]
  • Phytosterol (including β-sitosterol) content may contribute the same mechanisms seen above[13][15]

Other, uncontrolled evidence:

  • Theil 2022 noninterventional cohort: 130 men enrolled for up to 24 months, with 83 analyzed at 12 months. Mean IPSS change at 12 months was −4.7 points (95% CI −5.4 to −3.9); 62/83 (74.7%) had a ≥3-point reduction. IPSS-QoL "mostly satisfied" rose from 9/83 (11%) to 51/83 (61%) in that analyzed group. Sexual-function scores did not worsen in this uncontrolled cohort.[16]
  • Leibbrand 2019 single-arm pilot, n = 60 enrolled (n = 56 per-protocol analysis): at 12 weeks, mean IPSS fell 30.1% from baseline; mean PVR fell from 83.7 to 63.1 mL.[17]

4. Pygeum africanum (African Plum Tree Bark)​

Used in Europe for BPH since 1969. Older reviews report a short-term signal.[19][21]

Mechanism:

  • Anti-inflammatory. Decreased leukotrienes and 5-LOX metabolites[19]
  • Antifibroblast in the prostate[19]
  • Antiandrogenic. N-butylbenzenesulfonamide (NBBS) from dichloromethane extract acts as an androgen-receptor antagonist[20]
  • Modulates bladder contractility and restores prostate-epithelium secretory activity[19]

Evidence:

  • Wilt 2002 Cochrane review (subsequently withdrawn) included 18 RCTs (n = 1,562; mean duration 64 days). Six trials (n = 474) yielded a combined symptom/flow effect size of −0.8 SD (95% CI −1.4 to −0.3), not an IPSS change. In five trials (n = 430), physician-rated overall improvement was 65% versus 30% (RR 2.1, 95% CI 1.4–3.1). The nocturia difference versus placebo was −0.91 voids/night (−19%; 95% CI −1.95 to +0.14; three trials, n = 325), which did not establish a nocturia benefit. Versus placebo, Qmax was 2.5 mL/s higher (+23%; four trials, n = 363) and PVR was 13 mL lower (−24%; two trials, n = 264).[19][21]
  • Ishani 2000 meta-analysis. Ishani 2000 and the later 2002 Cochrane review each reported 18 RCTs (n = 1,562); dropout was 13% with Pygeum and 11% with placebo.[19][21]

Limitations: short mean duration of approximately 64 days, inconsistent reporting of means and SDs limits meta-analysis precision, no long-term or disease-progression data.[21]

Cernilton (Secale cereale pollen extract): a Cochrane review of four small trials (n = 444, 12–24 weeks) found modest improvement in self-rated symptoms and nocturia, with no improvement in flow, residual volume or prostate size, and rare, mild adverse events. Preparation quality was unknown and the comparators were unproven.[26] The 2000 review was withdrawn in 2011 because the authors did not update it.[28] It has no guideline recommendation.

Comparing the Evidence​

PreparationWhat the evidence supportsMain limitation
Serenoa repens overallCochrane: short-term IPSS difference about −0.90 points versus placebo; little/no clinically important symptom or quality-of-life benefit.[4]Preparations vary; do not replace this estimate with an uncontrolled −5.73-point change.
Hexanic SerenoaSome mixed-design reviews report modest benefit; EAU weakly recommends hexane-extracted Serenoa for men with LUTS who want to avoid adverse effects, especially sexual adverse effects.[5][23]—
β-sitosterolOlder short trials report symptom/flow improvement.[10][11]Limited durability and progression evidence.
Pumpkin seed/extractGRANU extract arm negative; whole-seed result requires cautious interpretation.[24]Partial blinding and formulation differences.
PygeumOlder studies report modest short-term benefits.[19][21]Heterogeneous, short studies; no established progression prevention.

How to Counsel a Patient Who Asks About Phytotherapy​

Scenario 1. Patient already taking it and LUTS improved:

  • Confirm what they are taking.
  • Interpret PSA in the clinical context.[5] Studied Serenoa preparations have not shown the predictable PSA reduction expected with 5-ARIs.[5]
  • Discuss observed benefit, cost, product uncertainty and adverse effects.

Scenario 2. Patient asking whether to try phytotherapy instead of an α-blocker or 5-ARI:

  • Explain the limited evidence and the specific EAU option above. If a patient chooses a trial, agree on symptom reassessment and stopping criteria; do not substitute it for indicated treatment of obstruction, retention or renal risk.[22][23]
  • For progression prevention in symptomatic BPH with demonstrable enlargement, assess prostate size, PSA when clinically available, and progression risk for 5-ARI treatment. Phytotherapy has not established prevention of retention or need for BPH surgery.[23][25]

Scenario 3. Patient failing phytotherapy:

  • Reassess as with any failing medical therapy: symptom severity, PVR, consider pressure-flow testing when DU versus BOO remains uncertain and the result would guide treatment, particularly before invasive treatment[29], prostate size on imaging, and escalate to guideline-directed α-blocker ± 5-ARI ± surgery.

Practical Pearls and Perioperative Review​

  • Document the actual product and ingredients.
  • Avoid unsupported efficacy rankings. Older positive meta-analyses, mechanistic experiments and modern placebo-controlled trials answer different questions.
  • Progression prevention is unproven. Phytotherapy has not established prevention of retention or need for BPH surgery.
  • Review supplements with anesthesia before surgery and use the local discontinuation plan. Saw palmetto is generally considered to have a low likelihood of clinically important drug interactions,[27] but a case report described severe intraoperative hemorrhage in a saw-palmetto user with prolonged bleeding time that normalized after stopping it.[30] Ask about use before prostate, perineal or prosthetic surgery, especially with anticoagulants or antiplatelets.
  • Supplement quality varies. US herbal products are marketed as dietary supplements without premarket proof of efficacy or standardized content.

See Also​

References​

1. Arnold MJ, Gaillardetz A, Ohiokpehai J. "Benign prostatic hyperplasia: rapid evidence review." Am Fam Physician. 2023;107(6):613–622.

2. Barry MJ, Meleth S, Lee JY, et al. "Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial." JAMA. 2011;306(12):1344–1351. doi:10.1001/jama.2011.1364

3. Blair HA. "Hexanic extract of Serenoa repens (Permixon): a review in symptomatic benign prostatic hyperplasia." Drugs Aging. 2022;39(3):235–243. doi:10.1007/s40266-022-00924-3

4. Franco JV, Trivisonno L, Sgarbossa NJ, et al. "Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement." Cochrane Database Syst Rev. 2023;6:CD001423. doi:10.1002/14651858.CD001423.pub4

5. Vela-Navarrete R, Alcaraz A, Rodríguez-Antolín A, et al. "Efficacy and safety of a hexanic extract of Serenoa repens (Permixon) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies." BJU Int. 2018;122(6):1049–1065. doi:10.1111/bju.14362

6. Ye Z, Huang J, Zhou L, et al. "Efficacy and safety of Serenoa repens extract among patients with benign prostatic hyperplasia in China: a multicenter, randomized, double-blind, placebo-controlled trial." Urology. 2019;129:172–179. doi:10.1016/j.urology.2019.02.030

7. Ooi SL, Pak SC. "Serenoa repens for lower urinary tract symptoms/benign prostatic hyperplasia: current evidence and its clinical implications in naturopathic medicine." J Altern Complement Med. 2017;23(8):599–606. doi:10.1089/acm.2016.0302

8. Tamalunas A, Schierholz F, Poth H, et al. "Pine-extracted phytosterol β-sitosterol (APOPROSTAT Forte) inhibits both human prostate smooth muscle contraction and prostate stromal cell growth, without cytotoxic effects: a mechanistic link to clinical efficacy in LUTS/BPH." Pharmaceuticals (Basel). 2025;18(12):1864. doi:10.3390/ph18121864

9. Buț MG, Tero-Vescan A, Pușcaș A, Jîtcă G, Marc G. "Exploring the inhibitory potential of phytosterols β-sitosterol, stigmasterol, and campesterol on 5-alpha reductase activity in the human prostate: an in vitro and in silico approach." Plants (Basel). 2024;13(22):3146. doi:10.3390/plants13223146

10. Wilt T, Ishani A, MacDonald R, et al. "Beta-sitosterols for benign prostatic hyperplasia." Cochrane Database Syst Rev. 2000;(2):CD001043. doi:10.1002/14651858.CD001043

11. Wilt TJ, MacDonald R, Ishani A. "Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review." BJU Int. 1999;83(9):976–983. doi:10.1046/j.1464-410x.1999.00026.x

12. Berges RR, Windeler J, Trampisch HJ, Senge T. "Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia." Lancet. 1995;345(8964):1529–1532. doi:10.1016/s0140-6736(95)91085-9

13. Šamec D, Loizzo MR, Gortzi O, et al. "The potential of pumpkin seed oil as a functional food — a comprehensive review of chemical composition, health benefits, and safety." Compr Rev Food Sci Food Saf. 2022;21(5):4422–4446. doi:10.1111/1541-4337.13013

14. Medjakovic S, Hobiger S, Ardjomand-Woelkart K, Bucar F, Jungbauer A. "Pumpkin seed extract: cell growth inhibition of hyperplastic and cancer cells, independent of steroid hormone receptors." Fitoterapia. 2016;110:150–156. doi:10.1016/j.fitote.2016.03.010

15. Pagano E, Laudato M, Griffo M, Capasso R. "Phytotherapy of benign prostatic hyperplasia: a minireview." Phytother Res. 2014;28(7):949–955. doi:10.1002/ptr.5084

16. Theil G, Richter M, Schulze M, et al. "Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study." World J Urol. 2022;40(7):1769–1775. doi:10.1007/s00345-022-04036-w

17. Leibbrand M, Siefer S, Schön C, et al. "Effects of an oil-free hydroethanolic pumpkin seed extract on symptom frequency and severity in men with benign prostatic hyperplasia: a pilot study in humans." J Med Food. 2019;22(6):551–559. doi:10.1089/jmf.2018.0106

18. Wilt TJ, Ishani A, Rutks I, MacDonald R. "Phytotherapy for benign prostatic hyperplasia." Public Health Nutr. 2000;3(4A):459–472. doi:10.1017/s1368980000000549

19. Wilt T, Ishani A, MacDonald R, Rutks I, Stark G. "Pygeum africanum for benign prostatic hyperplasia." Cochrane Database Syst Rev. 2002;(1):CD001044. doi:10.1002/14651858.CD001044

20. Schleich S, Papaioannou M, Baniahmad A, Matusch R. "Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity." Planta Med. 2006;72(9):807–813. doi:10.1055/s-2006-946638

21. Ishani A, MacDonald R, Nelson D, Rutks I, Wilt TJ. "Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis." Am J Med. 2000;109(8):654–664. doi:10.1016/s0002-9343(00)00604-5

22. Allkanjari O, Vitalone A. "What do we know about phytotherapy of benign prostatic hyperplasia?" Life Sci. 2015;126:42–56. doi:10.1016/j.lfs.2015.01.023

23. EAU. Management of non-neurogenic male LUTS: disease management, plant extracts. 2026. Guideline.

24. Vahlensieck W, Theurer C, Pfitzer E, et al. Effects of pumpkin seed in men with lower urinary tract symptoms due to benign prostatic hyperplasia in the one-year, randomized, placebo-controlled GRANU study. Urol Int. 2015;94:286–295. doi:10.1159/000362903. PubMed.

25. Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline. American Urological Association; 2026.

26. Wilt T, MacDonald R, Ishani A, Rutks I, Stark G. "Cernilton for benign prostatic hyperplasia." Cochrane Database Syst Rev. 2000;(2):CD001042. doi:10.1002/14651858.CD001042

27. Asher GN, Corbett AH, Hawke RL. "Common herbal dietary supplement-drug interactions." Am Fam Physician. 2017;96(2):101–107. PubMed

28. Wilt TJ, MacDonald R, Ishani A, Rutks I, Stark G. "WITHDRAWN: Cernilton for benign prostatic hyperplasia." Cochrane Database Syst Rev. 2011;2011(5):CD001042. doi:10.1002/14651858.CD001042.pub2

29. EAU Guidelines Office. "Diagnostic Evaluation." EAU Guidelines on the Management of Non-neurogenic Male LUTS. 2026. Guideline chapter.

30. Cheema P, El-Mefty O, Jazieh AR. "Intraoperative haemorrhage associated with the use of extract of Saw Palmetto herb: a case report and review of literature." J Intern Med. 2001;250(2):167–169. doi:10.1046/j.1365-2796.2001.00851.x

31. Antoniou V, Gauhar V, Modi S, Somani BK. "Role of phytotherapy in the management of BPH: a summary of the literature." J Clin Med. 2023;12(5):1899. doi:10.3390/jcm12051899

32. Sarma AV, Wei JT. "Benign prostatic hyperplasia and lower urinary tract symptoms." N Engl J Med. 2012;367(3):248–257. doi:10.1056/NEJMcp1106637